Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Roche confirms AD drug dropped by the wayside; two other MAO-B inhibitors remain in development

Oct. 5, 1999

Lilly and Synaptic investigate potential of 5-HT1A antagonist in nicotine withdrawal

Oct. 5, 1999

Novel monoamine reuptake inhibitors designed at ADIR, particularly useful in depression

Oct. 5, 1999

New CRF antagonists codeveloped by Janssen and Neurocrine Biosciences

Oct. 5, 1999

SUN-N4057 reduces both brain and body temperature in cat model of stroke

Oct. 5, 1999

DuPont, Janssen and Neurocrine Biosciences establish CRF collaboration

Oct. 5, 1999

NeoTherapeutics initiates phase II trial to study effects of Neotrofin on the brain

Oct. 5, 1999

Continued focus at Neurogen on GABA-A receptor ligands

Oct. 1, 1999

New HMR compounds inhibit both neuronal apoptosis and cell cycle progression

Oct. 1, 1999

Gliatech completes phase I study of Perceptin

Oct. 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...